Novel loci associated with eGFRcrea.
SNPs are listed in the stratum where the smallest P value in the discovery analysis was observed. Sample size/number of studies in the discovery phase: 74,354/26 (overall, direction test), 66,931/24 (No Diabetes), 46,435/23 (age ≤65 years); replication phase: 56,246/19 (overall, direction test), 41,218/17 (No Diabetes), 28,631/16 (age ≤65 years); combined analysis: 130,600/45 (overall, direction test), 108,149/41 (No Diabetes), 75,066/39 (age ≤65 years).
Chr.: chromosome; bp: base-pairs; Ref./Non-Ref. All.: reference/non-reference alleles; RAF: reference allele frequency; SE: standard error.
‡Genes nearby were based on RefSeq genes (build 36). The gene closest to the SNP is listed first and is in boldface if the SNP is located within the gene.
§Effects on log(eGFRcrea); post GWAS meta-analysis genomic control correction applied to P values and SEs.
*While being uncovered in the younger samples, this locus showed consistent results in the non-diabetic group (combined-analysis P value 5.7×10−16) and in the overall population (P value 9.5×10−22) - see Tables S16 and S10 for additional details.
**The direction test was performed in the overall dataset; the genomic control corrected P value from the direction test for the SNP rs2928148 was 4.0×10−7. In the combined analysis, the largest effect size (0.0054 on log eGFR in ml/min/1.73 m2) and the smallest P value (3.7×10−8) were observed in the non-diabetic group.
†All results were confirmed by random-effect meta-analysis.